Abstract: To provide a functional structural body that can realize ong life time by suppressing the decline in function of the functional substance and that can attempt to save resources without requiring a complicated replacement operation, and to provide a method for making the functional structural body. The functional structural body (1) includes a skeletal body (10) of a porous structure composed of a zeolite-type compound, and at least one functional substance (20) present in the skeletal body (10), the skeletal body (10) has channels (11) connecting with each other, and the functional substance is present at least the channels (11) of the skeletal body (10).

Abstract: A functional structural body includes a skeletal body of a porous structure composed of a zeolite-type compound, and at least one type of metallic nanoparticles present in the skeletal body, the skeletal body having channels connecting with each other, the metallic nanoparticles being present at least in the channels of the skeletal body.

Abstract: Provide is a functional structural body that can suppress aggregation of metal oxide nanoparticles and prevent functional loss of metal oxide nanoparticles, and thus exhibit a stable function over a long period of time. A functional structural body (1) includes: a skeletal body (10) of a porous structure composed of a zeolite-type compound; and at least one type of metal oxide nanoparticles (20) containing a perovskite-type oxide present in the skeletal body (10), the skeletal body (10) having channels (11) that connect with each other, and the metal oxide nanoparticles (20) being present at least in the channels (11) of the skeletal body (10).

Abstract: A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): [in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R3 and R4 each independently represents a C1-4 alkyl group or a C2-4 alkenyl group, where, R3 and R4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C1-4 alkyl groups or C2-4 alkenyl groups may be substituted on the ring)].

Abstract: A freshness/degree of maturation evaluating device for evaluating freshness and/or degree of maturation of food animal, freshness/degree of maturation evaluating device provided with: temperature parameter calculation unit that calculates temperature parameter regarding storage time and temperature in arbitrary area inside food animal, parameter based on temperature in arbitrary area inside food animal, determined by storage time and unsteady heat conduction equation; rate constant parameter calculation unit that calculates rate constant parameter regarding sequential decomposition reactions of various ATP-associated compounds contained infood animal, parameter being set based on rate constants in food animal determined by using relation based on storage time of food animal and measured values of ATP-associated compound concentrations; ATP-associated compound concentration calculation unit that calculates ATP-associated compound concentrations by sequential decomposition reaction calculation model using tempe

Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula (I): wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound. An arenavirus proliferation inhibitor comprising a compound represented by Formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Abstract: A neural network circuit is provided with which it is possible to significantly reduce the area occupied by the connection unit of a full connection (FC)-type neural network circuit. An analog-type neural network circuit constitute a learning apparatus having a self-learning function and corresponding to a brain function, wherein the neural network comprises: a plurality (n) of input-side neurons; a plurality (m, and including cases when n=m) of output-side neurons; (n×m) connection units each connecting one input-side neuron and one output-side neuron; and a self-learning control unit, the (n×m) connection units being constituted from connection units corresponding to only the positive weighting function as a brain function, and connection units corresponding to only the negative weighting function as the brain function.

Abstract: A rod group includes a plurality of first rods that has an arcuate first curve, the first rods having mutually different lengths; and a plurality of second rods that has an S-shaped second curve, the second rods having mutually different lengths. The first rods and the second rods have shapes for treatment of scoliosis by (i) guiding the postoperative apex of the thoracic kyphosis to be located at the thoracic vertebrae T6 to T8, and (ii) guiding a postoperative apex of the thoracic kyphosis to be located at a position different from a preoperative apex of the thoracic kyphosis and the second rod each have a shape extending along an anatomically normal spinal column arrangement.

Abstract: The present invention relates to an agent for protection of vascular endothelial cells, an agent for protection of blood brain spinal cord barrier, and an agent for protection of central nervous system, containing at least one compound selected from the group consisting of muvritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition for the treatment of diseases associated with blood brain spinal cord barrier disruption, containing at least one compound selected from the group consisting of muvritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof.

Abstract: A copolymer comprising: a hydroxycarboxylic acid (A) having a hydroxy group only at a 2-position; and a hydroxycarboxylic acid (B) having a hydroxy group at a position other than a 2-position, and having a homopolymer segment composed of one hydroxycarboxylic acid selected from the group consisting of the hydroxycarboxylic acid (A) and the hydroxycarboxylic acid (B), and a copolymer segment containing at least two hydroxycarboxylic acids selected from the group consisting of the hydroxycarboxylic acid (A) and the hydroxycarboxylic acid (B).

Abstract: An optical filter includes a first loop mirror, a second loop mirror, a first waveguide optically coupled to the first loop mirror and the second loop mirror, a second waveguide optically coupled to the first loop mirror and the second loop mirror, a first access waveguide optically coupled to the first waveguide, a second access waveguide optically coupled to the second waveguide, and an output section, wherein the first loop mirror includes a first loop waveguide and a first multiplexer/demultiplexer, the second loop mirror includes a second loop waveguide and a second multiplexer/demultiplexer, the output section includes a third loop waveguide, a third multiplexer/demultiplexer, a third waveguide, and a fourth waveguide, the third loop waveguide optically coupled to the second loop waveguide and the third multiplexer/demultiplexer, the third waveguide and the fourth waveguide optically coupled to the third multiplexer/demultiplexer, and the output section.

Abstract: Disclosed is a rare earth complex including: one or a plurality of rare earth ions; and a ligand forming a coordinate bond with the rare earth ions. At least a part of the rare earth ions are at least one kind selected from the group consisting of lutetium(III) ions, yttrium(III) ions, and gadolinium(III) ions. The ligand includes a residue obtained by removing one or more hydrogen atoms from a fluorescent condensed polycyclic aromatic compound.

Abstract: Provided is a composition for treating cartilage injury lesion that is combined with a concentrated bone marrow aspirate and applied to a cartilage injury lesion, that has flowability when applied to the cartilage injury lesion, and that contains a monovalent metal salt of alginic acid. Thereby, a novel composition for treating cartilage injury lesion that can be used to restore and/or regenerate cartilage tissue is provided.

Abstract: [Problem] An object of the present invention is to produce cancer cell clusters with intrinsic biological properties as cancer tissues, such as morphological polarity and tissue motion polarity, in vitro. [Solution] The present invention relates to a cell culture substrate including a base material and a biocompatible polymer layer, the substrate including a plurality of rough sections on the surface of the substrate, wherein the rough sections are not covered with the biocompatible polymer layer, have a predetermined surface structure with a predetermined shape, and are disposed at predetermined intervals. With the present invention, it is possible to obtain a live cancer cell aggregate having morphological polarity and tissue motion polarity similar to that observed in vivo, by a very easy operation of culturing cancer cells on a cell culture substrate having a predetermined structure, thereby performing live imaging of microtumors in vitro is enabled, which has been conventionally impossible.

Abstract: The present invention relates to a method of producing a chitin oligomer, including subjecting chitin-containing biomass to partial hydrolysis while pulverizing the chitin-containing biomass with a pulverization apparatus in the co-presence of water and an acid catalyst selected from phosphoric acid, nitrous acid, and an organic acid (Method 1); a method of producing N-acetylglucosamine, including hydrolyzing a chitin oligomer obtained by the Method 1 by adding water thereto, followed by heating (Method 2); and a method of producing a 1-O-alkyl-N-acetylglucosamine, including alcoholyzing a chitin oligomer by adding an alcohol thereto (Method 3).

Abstract: Provided is a method of assisting the detection of nonalcoholic steatohepatitis (NASH), which is far less invasive than liver biopsy and is based on simple operations that do not require skilled technical personnel. The present invention is a method of assisting the detection of NASH, which includes: a) measuring the amount of LDL-TG contained in a test blood sample isolated from a living body; b) measuring the amount of at least one component selected from the group consisting of LDL-C, LDL subfraction-C, IIDL-C, HDL subfraction-C, ApoB, ApoE, total cholesterol, ALT, and AST contained in the test blood sample; and c) determining the possibility of developing and/or having NASH by using the amount of LDL-TG in combination with the amount of the at least one component.

Abstract: To provide novel low-temperature sinterable copper particles that can be sintered even at a low temperature of, for example, around 100° C. or less, and a method for producing a sintered body by using the same. The low-temperature sinterable copper particles according to the present invention are coated with a carboxylic acid, and a surface of the copper particle is oxidized so as to have a cuprous oxide fraction (Cu2O/(Cu+Cu2O)) in the copper particle of 4% by mass or less or so as to have an average coating thickness of cuprous oxide of 10 nm or less. The low-temperature sinterable copper particles are subjected to low-temperature firing in an atmosphere of 0.01 Pa or less.

Abstract: Realized is reliable fixation of a material in a fluid state containing a monovalent metal salt of alginic acid when the material is applied to a subject. A combination of compositions comprising a first material composition containing a monovalent metal salt of alginic acid and a second material composition containing a cross-linking agent having an action of cross-linking the monovalent metal salt of alginic acid, wherein the combination is to be used in such a way as to apply the first material composition to a subject in a fluid state and contact the second material composition with the first material composition applied to the subject to gel at least a part of the first material composition, wherein the first material composition further contains a coloring component so that a formation state of a gel coat on a surface of the first material composition applied to the subject can be evaluated.

Abstract: A retractor is provided that can form a joint cavity internal space for a field of view for an endoscope and practice of a treatment in a state where a wound area is spread. A retractor includes first arm portions 2 and 3 and a second arm portion 4 positioned between the first arm portions 2 and 3. The first arm portions 2 and 3 include first claw portions 12 and 13 to be hung on a wound area entrance edge. The second arm portion 4 includes a second claw portion 14 to be hung on the wound area entrance edge. When the first arm portions 2 and 3 and the second arm portion 4 are in a closed state, the first claw portions 12 and 13 and the second claw portion 14 overlap with each other.